ABSTRACT
@#The second near-infrared window(NIR-II)fluorescent dye IR-1061 has the disadvantage of poorwater solubility and low quantum yield, which limits its application in biomedicine. We used liposomes as the carrier to increase their water solubility, and co-loaded a near-infrared region(NIR-I)fluorescent dye IR-780 into liposomes to enhance the fluorescence intensity of IR-1061 in NIR-II. Results showed that the liposomes exhibited significantly enhanced characteristic fluorescence under 980 nm laser irradiation. In addition, particle size, appearance, photothermal conversion efficiency, photoacoustic performance and cytotoxicity of liposomes were examined. This study showed that these combined liposomes exhibited potential as a NIR-II fluorescence/photoacoustic bimodal imaging system for the diagnosis and guidance of tumor photothermal therapy.
ABSTRACT
@#The combination of diagnosis and treatment through nanotechnology is conducive to the development of cancer treatment. Fluorescent imaging in the second near-infrared window(NIR-II)developed rapidly in recent years due to its imaging advantages. In this paper, we prepared a novel nano drug system, DOX-IR1061-cationic liposome, in which NIR-II fluorescent probe IR1061 was loaded as imaging agents and doxorubicin was loaded as therapeutic agents. It also explores enhanced cellular uptake and cancer cell inhibition rate through octadecylamine. Our NIR-II performance test on liposomes showed that DOX-IR1061-cationic liposome has NIR-II imaging ability. Analysis of liposome cell uptake behavior and cancer cell inhibition experiments demonstrated that octadecylamine can promote liposome uptake by cells and synergize with DOX to enhance anticancer effects. This suggests that the DOX-IR1061-cationic liposome can be used to achieve imaging and therapy effect with further research value.
ABSTRACT
Objective To explore the clinical value and significance of the chronic obstructive pulmonary disease (COPD) assessment test (CAT) in patients with acute exacerbation of COPD (AECOPD).Methods A prospective observational study was conducted,AECOPD patients were admitted to the Department of Respiration Medicine in Jiaxing Second Hospital from February 2011 to July 2016 were enrolled,and they all underwent CAT assessment test and lung function examination.The patients were assigned to Ⅱ,Ⅲ and Ⅳ grade groups according to the lung function level,and the difference of forced expiratory end volume in 1 second (FEV1) and FEV1/forced vital capacity (FVC) ratio were compared among the three groups;the patients were also assigned into 2,3 and 4 grade groups according to CAT scores,and the difference of length of stay in the hospital and hospitalization expenses were compared among the three groups.Spearman correlation analysis was used to analyze the correlations between the CAT score and lung function indexes.Results One hundred and thirty-five patients with AECOPD were accepted and all of their clinical data were analyzed in the study.Their mean FEV1 was (0.42±0.16) L,FEV1/FVC was 0.44 ±0.13 and CAT score was 26.64 ± 5.43.The correlation analyses showed:there were significant negative correlations between CAT score and FEV1,FEV1/FVC (r value was-0.691,-0.728,both P ＜ 0.001).With the elevation of lung function grade,FEV1 and FEV1/FVC were decreased gradually (1Ⅱ,Ⅲ,Ⅳ grade groups were 0.62±0.07,0.40±0.06,0.25±0.03 and 0.64±0.01,0.40±0.00,0.33±0.06 respectively),while CAT score raised gradually (20.03 ± 3.36,28.30 ± 3.31,30.18±3.86,all P ＜ 0.01);with the CAT score getting higher and higher,hospitalization expenses (yuan) and the length of stay in hospital (day) of patients with AECOPD were increased significantly (2,3,4 grade groups:expense were 6214.09±1396.16,8339.31±1866.46,9600.97±4339.87,and length of stay in hospital were 7.54± 1.62,9.52±2.21,14.85 ±5.62,respectively,all P ＜ 0.01).Conclusion CAT is a reliable tool to measure the life quality of AECOPD patients and has certain relevance to the severity and prognosis of the disease.
ABSTRACT
Objective To compare large dose or conventional dose of budesonide/formoterol fumarate powder in treatment of stable chronic obstructive pulmonary disease(COPD).Methods 120 patients with stable COPD from March 2015 to March 2016 in Jiaxing Second hospital were selected,were treated with budesonide/formoterol,and were divided into the conventional dose group and high dose groupaccording to different doses,60 cases in each group.Pulmonary function tests,CAT Chinese version scale assessment and 6 min walking distance(6MWD)test were performed before and after treatment,and adverse reactions and acute attack were observed.Results FEV1/FVC and FEV1％were significantly improved after treatment in the two groups,and those in the high dose group were significantly better than those in the conventional dose group,the difference was statistically significant(P<0.05),CAT score and 6MWD were significantly improved after treatment in the two groups,and those in the high dose group were significantly higher than those in the conventional dose group,the difference was statistically significant(P<0.05),adverse reactions such as palpitations,tachycardiain the high dose group were significantly higher than those in the conventional dose group,while the acute attack rate was significantly lower than that of the conventional dose group,the difference was statistically significant(P<0.05).Conclusion High dose of budesonide/formoterol inhalation in the treatment of patients with stable COPD powder can improve the pulmonary function and health status,but adverse reactions increase.